After failed to achieve the approval of US Food and Drug Administration, ReNeuron get UK Medicines and Healthcare Products Regulatory Agency (MHRA) approval of clinical trial of its stroke patients. Scotland will be the first place in the world to witness embryonic stem cell treatment of a dozen patients suffering from stroke.
Researchers will inject “neural stem cells” into the brain of stroke patients, derived from the brain cell of an aborted fetus. Keith Muir, a neurologist at Glasgow University, will lead the trial at the city’s Southern General Hospital.
This neural stem cell comes from a stem-cell line grown from a tissue sample taken at least five years ago from the brain of an aborted fetus,
previous animal tests suggest that the stem cells derived from a cell line that originated several years ago from an aborted human foetus - will help the patient’s brain to regenerate, reversing some of the damage caused by the stroke.
Scientists are eagerly looking to see some recovery for the patients, which will allow them lead quality independent lives.
However, while FDA being too risk averse, avoiding the authorisation of new tests and medicines, but Its European counterpart has already approved a number of trials and drugs more rapidly, including a new procedure allowing biological generic medicines for the first time.